Skip to main content
SpringerLink
Log in
Book cover

Cancer Drug Delivery Systems Based on the Tumor Microenvironment pp 269–288Cite as

CAST Therapy

  • Chapter
  • First Online:

  • 606 Accesses

Abstract

Cancer consists not only of tumor cells but also of tumor stroma. The latter has various components such as fibroblasts, mesenchymal cells, blood vessels or extracellular matrix proteins (e.g. collagen, fibronectin or fibrin). (See chapter by Tarin describing the pathogenesis of cancer and stromal changes during the process). Moreover, it also promotes tumor cell growth, survival, invasion and metastasis. It is thus increasingly important to understand the role of tumor stroma in tumorigenesis and tumor progression. In this chapter, stroma-mediated drug-resistance and methods to overcome it are described and evaluated.

Most recently, antibody-drug conjugates (ADCs), consisting of an antibody and a cytotoxic drug connected via a specialized linker have become available as a next generation of antibody therapeutics, intended to enhance focused delivery of anti-cancer agents into the internal tumor environment.

However, none of them has been proved to be effective in treating refractory cancers such as pancreatic cancer or scirrhous gastric cancer. These cancers are known to possess abundant stroma, which hinders the distribution of therapeutic antibodies and ADCs within the cancerous growth. This is the so-called tumor stromal barrier.

To overcome this drawback, we have developed a unique type of ADC, namely, cancer stromal targeting (CAST) therapy, in which stroma targeting mAbs (anti-collagen 4 or anti-insoluble fibrin (IF) mAbs) were conjugated with anticancer agents. Our results confirmed that ADCs bound to collagen 4 or IF in the stroma, from which effective sustained release of the drugs occurred. The released drug subsequently diffused through the tumor tissue, causing marked arrest of tumor growth associated with damage to tumor blood vessels and death of cancer cells.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Diamantis N, Banerji U (2016) Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer 114:362–367. https://doi.org/10.1038/bjc.2015.435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mack F, Ritchie M, Sapra P (2014) The next generation of antibody drug conjugates. Semin Oncol 41:637–652. https://doi.org/10.1053/j.seminoncol.2014.08.001

    Article  CAS  PubMed  Google Scholar 

  3. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631–637. https://doi.org/10.1038/nbt.2289

    Article  CAS  PubMed  Google Scholar 

  4. Thomas A, Teicher BA, Hassan R (2016) Antibody-drug conjugates for cancer therapy. Lancet Oncol 17:e254–e262. https://doi.org/10.1016/s1470-2045(16)30030-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pro B et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 30:2190–2196. https://doi.org/10.1200/jco.2011.38.0402

    Article  CAS  Google Scholar 

  6. Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK (2017) Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discov Today 22:1547–1556. https://doi.org/10.1016/j.drudis.2017.05.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Younes A et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 30:2183–2189. https://doi.org/10.1200/jco.2011.38.0410

    Article  CAS  Google Scholar 

  8. Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. https://doi.org/10.1056/NEJMoa1209124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Matsumura Y (2012) Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 64:710–719. https://doi.org/10.1016/j.addr.2011.12.010

    Article  CAS  PubMed  Google Scholar 

  10. Matsumura Y et al (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol Off J Eur Soc Med Oncol 15:517–525

    Article  CAS  Google Scholar 

  11. Yasunaga M, Manabe S, Matsumura Y (2011a) New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 102:1396–1402. https://doi.org/10.1111/j.1349-7006.2011.01954.x

    Article  CAS  PubMed  Google Scholar 

  12. Yasunaga M, Manabe S, Tarin D, Matsumura Y (2011b) Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 22:1776–1783. https://doi.org/10.1021/bc200158j

    Article  CAS  PubMed  Google Scholar 

  13. Yasunaga M, Manabe S, Tarin D, Matsumura Y (2013) Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci 104:231–237. https://doi.org/10.1111/cas.12062

    Article  CAS  PubMed  Google Scholar 

  14. Shimokawa M et al (2017) Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 545:187–192. https://doi.org/10.1038/nature22081

    Article  CAS  PubMed  Google Scholar 

  15. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768. https://doi.org/10.1038/nrc2499

    Article  CAS  PubMed  Google Scholar 

  16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988. https://doi.org/10.1073/pnas.0530291100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

    Article  CAS  PubMed  Google Scholar 

  18. Lapidot T et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648. https://doi.org/10.1038/367645a0

    Article  CAS  PubMed  Google Scholar 

  19. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. https://doi.org/10.1038/nature05372

    Article  CAS  PubMed  Google Scholar 

  20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115. https://doi.org/10.1038/nature05384

    Article  CAS  PubMed  Google Scholar 

  21. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111. https://doi.org/10.1038/35102167

    Article  CAS  PubMed  Google Scholar 

  22. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (New York, NY) 219:983–985

    Article  CAS  Google Scholar 

  23. Matsumura Y, Kimura M, Yamamoto T, Maeda H (1988) Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 79:1327–1334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109–119. https://doi.org/10.1007/s10456-008-9099-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392

    CAS  PubMed  Google Scholar 

  26. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157. https://doi.org/10.1038/nbt1137

    Article  CAS  PubMed  Google Scholar 

  27. Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32:3494–3507. https://doi.org/10.1007/s11095-015-1624-3

    Article  CAS  PubMed  Google Scholar 

  28. Doronina SO et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784. https://doi.org/10.1038/nbt832

    Article  CAS  PubMed  Google Scholar 

  29. Lyon RP et al (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733–735. https://doi.org/10.1038/nbt.3212

    Article  CAS  PubMed  Google Scholar 

  30. Yasunaga M et al (2017) Development of antibody-drug conjugates using DDS and molecular imaging. Bioengineering (Basel, Switzerland) 4(3):78. https://doi.org/10.3390/bioengineering4030078

    Article  CAS  Google Scholar 

  31. Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC (2018) Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel, Switzerland) 11(2):32. https://doi.org/10.3390/ph11020032

    Article  CAS  Google Scholar 

  32. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659. https://doi.org/10.1056/nejm198612253152606

    Article  CAS  PubMed  Google Scholar 

  33. Hisada Y et al (2013) Discovery of an uncovered region in fibrin clots and its clinical significance. Sci Rep 3:2604. https://doi.org/10.1038/srep02604

    Article  PubMed  PubMed Central  Google Scholar 

  34. Fuchigami H, Manabe S, Yasunaga M, Matsumura Y (2018) Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Sci Rep 8:14211. https://doi.org/10.1038/s41598-018-32601-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801–1815. https://doi.org/10.1016/s0002-9440(10)63540-7

    Article  PubMed  PubMed Central  Google Scholar 

  36. Hingorani SR et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483. https://doi.org/10.1016/j.ccr.2005.04.023

    Article  CAS  PubMed  Google Scholar 

  37. Obonai T, Fuchigami H, Furuya F, Kozuka N, Yasunaga M, Matsumura Y (2016) Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. Sci Rep 6:23613. https://doi.org/10.1038/srep23613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Catenacci DV et al (2015) Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:4284–4292. https://doi.org/10.1200/jco.2015.62.8719

    Article  CAS  Google Scholar 

  39. Hurwitz H et al (2018) Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investig New Drugs 36:683–695. https://doi.org/10.1007/s10637-018-0580-2

    Article  CAS  Google Scholar 

  40. Hingorani SR et al (2016) Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res 22:2848–2854. https://doi.org/10.1158/1078-0432.ccr-15-2010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Olive KP et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, NY) 324:1457–1461. https://doi.org/10.1126/science.1171362

    Article  CAS  Google Scholar 

  42. Laing N et al (2013) Inhibition of platelet-derived growth factor receptor alpha by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol 83:1247–1256. https://doi.org/10.1124/mol.112.084079

    Article  CAS  PubMed  Google Scholar 

  43. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5:53. https://doi.org/10.1186/s40425-017-0257-y

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ostermann E et al (2008) Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 14:4584–4592. https://doi.org/10.1158/1078-0432.ccr-07-5211

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan

    Masahiro Yasunaga & Yasuhiro Matsumura

  2. Cluster for Pioneering Research, RIKEN, Wako, Japan

    Shino Manabe

  3. Research Center for Pharmaceutical Development, Tohoku University, Sendai, Japan

    Shino Manabe

Authors
  1. Masahiro Yasunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shino Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhiro Matsumura .

Editor information

Editors and Affiliations

  1. Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan

    Yasuhiro Matsumura

  2. Moores UCSD Cancer Center and Department of Pathology, University of California San Diego, La Jolla, CA, USA

    David Tarin

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Japan KK, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yasunaga, M., Manabe, S., Matsumura, Y. (2019). CAST Therapy. In: Matsumura, Y., Tarin, D. (eds) Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56880-3_12

Download citation

Publish with us

Policies and ethics

Search

Navigation